Novo Nordisk To Add 1,000 Workers Next Two Years In Emerging Markets
This article was originally published in PharmAsia News
Denmark's Novo Nordisk says it will add 1,000 workers over the next two years to offer more diabetes drugs to the emerging markets of Colombia, Egypt, Indonesia, Malaysia, Ukraine and Vietnam.
You may also be interested in...
US FDA investigators' increased focus on aseptic operations is resulting in more Form 483 observations of microbiological contamination issues over the past few years.
Pfizer's COVID-19 vaccine is sure to dominate the third quarter results call, with everything from data to widescale distribution and the potential financial reward on the minds of investors and the public.
The company’s third-quarter sales were up 4% year-over-year as transcatheter aortic valve replacement procedure volumes returned to pre-pandemic levels.